Sorin Group S.p.A. Announces U.S. Launch of New Heart Device for Simultaneous Implantation of an Aortic Tissue Valve and Ascending Aorta

Published: Nov 06, 2012

MILAN, Italy--(BUSINESS WIRE)--Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the U.S. commercial launch of the Mitroflow Valsalva ConduitTM, the only Valsalva conduit graft approved by the U.S. Food and Drug Administration (FDA) for use in combination with an aortic tissue valve. Previously available only with mechanical valves, Sorin Group’s innovative Mitroflow Valsalva Conduit now offers cardiac surgeons a solution for replacing simultaneously the ascending aorta and the diseased aortic valve with Sorin’s highly durable MitroflowTM pericardial aortic valve.

Back to news